Business Wire

Prohibition at Any Cost? Philip Morris International Hits Back at Global Campaign of Disinformation

21.2.2020 16:58:00 EET | Business Wire | Press release

Share

Statement by Dr. Moira Gilchrist BSc (Hons) Pharmacy, PhD Pharmaceutical Sciences, Vice President Strategic & Scientific Communication, Philip Morris International:

“‘You should develop a safer product.’ For decades, that is what governments and the public health community have told the tobacco industry. PMI has invested billions of dollars in science and technology to achieve that precise objective.

“A campaign coordinated by American special interest groups, all of whom are seemingly funded by the same source—Bloomberg Philanthropies—are dedicated to just one mission. Under the guise of promoting public health, they are working to rob adults who smoke of their right to choose scientifically substantiated better alternatives to continued smoking. We have a question for them: Why are they using an elaborate network of organizations to deceive adults who smoke, elected officials, and the public health community? We can only conclude that they are pursuing a disastrous prohibition-only crusade. We urge these groups to: STOP ignoring the rights of hundreds of millions of adults who smoke and who deserve better alternatives; STOP ignoring science and evidence that doesn’t fit with their dogma; and START having a real conversation.

“This dangerous and misguided campaign has provided grants to media for journalism that many people believe is independent. Ultimately, this undermines the goal of harm reduction and confuses adults who smoke about better choices. And ironically, the campaign attacks the only company that has publicly committed to eliminate cigarettes.

“If people who smoke are denied accurate information—or worse yet, are deceived—about less harmful alternatives, the vast majority will simply continue to smoke cigarettes.

“To set the record straight we have addressed all of the allegations made against us by this global campaign on our website: PMI.com. We invite everyone to learn the facts, study our science and arrive at their own conclusions. We have nothing to hide.”

Background

We are moving as fast as we can, but more importantly adults who smoke are voting with their feet and switching as fast as they can.

We have been clear about our objective to end cigarette sales. This is the future of our company; for PMI there is no turning back. We have the determination to make it work.

The proof is in the numbers:

  • Smoke-free products are now almost a fifth of our business—up from zero five years ago
  • Since 2008, we have invested $7.2 billion to develop and scientifically substantiate smoke-free alternatives
  • Nearly 10 million adults have completely stopped smoking cigarettes and switched to our electrically heated tobacco system, which is now available in 52 markets
  • Whilst cessation is clearly the best option, our market research across many countries indicates that 80% of adults who smoke want better alternatives
  • In 2019, 71 percent of our commercial spend was dedicated to smoke-free products

These facts are the real story.

The question for our critics is this: do they want to make our transformation away from cigarettes slower or faster? Do they want it to make it more difficult for adults who would otherwise continue smoking to choose better products, or less difficult?

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of December 31, 2019, PMI estimates that approximately 9.7 million adult smokers around the world have already stopped smoking and switched to PMI's heat-not-burn product, available for sale in 52 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Fraser
Philip Morris International
T. +41 (0)58 242 4500
E. David.Fraser@pmi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release

Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix

Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe

Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release

As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity

Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release

Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with

Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 07:55:00 EET | Press release

Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye